![](https://www.myesr.org/app/uploads/2023/10/ai-blog-image-18-768x605.jpg)
MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma
Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis. For a decade, sorafenib, a multi-kinase inhibitor, was the only approved systemic therapy for HCC. However, its response rate in advanced HCC is only about 2%. The last few years have seen rapid approval of additional systemic therapies for HCC, including immunotherapy strategies. Immune checkpoint inhibitor nivolumab has a promising reported response